Agoracom Blog Home

Posts Tagged ‘pharma’

VIDEO – AGORACOM Beyond The Expert With Venture Capitalist Leigh Hughes Discusses Small Cap Esports: $GMBL; $FANS / $FUNFF; $TGS; $ITM

Posted by AGORACOM-JC at 5:50 PM on Wednesday, March 3rd, 2021

AGORACOM followers have given us great feedback on our hit series “Beyond The Press Release” (BTPR) in which we speak with small cap CEO’s about important press releases in greater depth and, quite frankly, in layman’s terms for investors to truly understand their significance.

Whereas BTPR tells these stories from the side of small cap public companies, Beyond The Expert (BTE) tells these stories from the perspective of experts on these topics – and we couldn’t think of anyone better to start off this series than Leigh Hughes.

Leigh is a Venture Capitalist who I’ve personally watched conduct incredible due diligence and invest into many small cap companies that have generated incredible returns over 12-18 month periods.  

Leigh is so good at what he does that many global private equity funds and institutions take his call and often follow him into investments he chooses to make.  Moreover, he serves as an advisor to several small cap companies.

If you ever wanted to truly learn how to become a great small cap investor, it doesn’t get much better than this.

On today’s episode we discuss the outlook for esports, why it is so explosive and a few small cap esports companies to consider including:

  • Esports Entertainment Group (GMBL:NASDAQ)
  • FansUnite Entertainment (FANS:CSE / FUNFF:OTCQB)
  • TGS Esports (TGS:TSXV)
  • …. and newcomer Intema Solutions (ITM:TSXV) Who recently completed their acquisition of HypeX

Without further adieu, watch this great interview with Leigh Hughes and make sure to provide us with your feedback via comments on Twitter, YouTube or wherever you may be watching or listening.

Valeo Pharma $VPH $VPHIF Reports its 2020 Fourth Quarter and Year-End Results and Highlights $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 5:52 PM on Wednesday, February 24th, 2021
Valeo Pharma (@valeo_pharma) | Twitter
  • Q4-20 net revenues of $2.2 million , up 76 % vs Q4-19, 2020 net revenues of $7.5 million up 14% vs 2019
  • Hiring of Frederic Fasano as new President and COO
  • Successfully launched 4 new products during FY-20
  • Redesca ® , Redesca HP ® and Amikacin approved by Health Canada subsequent to year-end
  • $10.8 million raised in 2020 from bought deal offering and over-subscribed private placements
  • Valeo’s shares now trading on the US-OTCQB exchange under “VPHIF”

MONTREAL , Feb. 24, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian specialty pharmaceutical company, today reported its financial results for the fourth quarter and year-ended October 31, 2020 .

“Valeo accomplished key objectives in 2020 which sets the stage for strong growth in 2021. In addition to Hesperco TM , we launched three strategic products and secured regulatory approvals for Redesca ® ,Redesca HP ® and Amikacin, all of which will be launched in the first half of 2021. We expect that these products will contribute significant revenues and margins in 2021”, said Steve Saviuk , Valeo’s CEO. “Our vision of building an anchor Canadian pharmaceutical company through therapeutic innovation is solidifying as we continue to build our commercial portfolio in therapeutic areas of focus.”

Commenting on the fourth quarter and 2020 results, Luc Mainville , Senior Vice-President and Chief Financial Officer said, “As evidenced by our revenues increase and net loss decrease of the fourth quarter, our efforts towards becoming a profitable EBITDA company are starting to bear fruit. During the last portion of 2020, the launch of new products such as Ametop ® and Yondelis® in Canada and Sodium Ethacrynate in the U.S., has contributed new revenues and margins with nominal increase to our operating expenses. The execution of our growth strategy is positioning the Company for a very successful year in 2021”.

Read More: https://agoracom.com/ir/ValeoPharma/forums/discussion/topics/756027-valeo-pharma-reports-its-2020-fourth-quarter-and-year-end-results-and-highlights/messages/2305248#message

VIDEO – Valeo Pharma $VPH $VPHIF Hesperco Capsules at Core of Montreal Heart Institute’s Coronavirus Clinical Trial $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 7:38 PM on Sunday, February 21st, 2021
Valeo Pharma (@valeo_pharma) | Twitter

Valeo Pharma $VPH $VPHIF to Report Fourth Quarter and 2020 Year-End Results and Hold Investors Conference Call / Webcast $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 8:19 AM on Friday, February 19th, 2021
Valeo Pharma (@valeo_pharma) | Twitter
  • Valeo will host a conference call to discuss those results and highlights on Thursday February 25, 2021 at 8.30am (EST) .
  • The telephone numbers to access the conference call are 1-888-231-8191 and 647-427-7450.

MONTREAL , Feb. 19, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian specialty pharmaceutical company, announced today that it will report its financial results and highlights for the fourth quarter and year ended October 31, 2020 on Wednesday February 24, 2021 after market close.

Valeo will host a conference call to discuss those results and highlights on Thursday February 25, 2021 at 8.30am (EST) . The telephone numbers to access the conference call are 1-888-231-8191 and 647-427-7450. An audio replay of the call will be available. The numbers to access the audio replay are 1-855-859-2056 and 416-849-0833 using the following access code (1498873).

A live audio webcast of the conference call will be available via: https://produceredition.webcasts.com/starthere.jsp?ei=1433860&tp_key=71fe5003d2

Valeo Pharma’s $VPH $VPHIF Hesperco Capsules at the Core of Montreal Heart Institute’s Hesperidin Coronavirus Clinical Trial $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 8:21 AM on Wednesday, February 17th, 2021
Valeo Pharma (@valeo_pharma) | Twitter
  • Montreal Heart Institute study to evaluate the ability of hesperidin, the medicinal ingredient in Hesperco™ capsules, to reduce the severity of symptoms and the need for hospitalization in COVID-19 patients
  • Hesperidin interferes / inhibits 2 key proteins of SARS-CoV-2 necessary for entry and infection of cells, suggesting that hesperidin may disrupt the replication rate of the virus and enable infected patients to build natural immunity
  • Hesperidin’s safety profile and immune-modulatory activity make it a highly promising molecule to intervene at various stages of the COVID-19 infection process
  • Hesperco TM capsules contain 500mg of high purity concentrated hesperidin

MONTREAL , Feb. 17, 2021 – Valeo Pharma Inc . ( CSE:VPH) (OTCQB:VPHIF) (FSE:VP2 ) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company and its Hesperco™ development partner, Ingenew Pharma Inc. (“Ingenew”), are pleased to announce that Hesperco TM capsules, approved by Health Canada for immune support, will be at the core of the Montreal Heart Institute’s (“MHI”) clinical trial, “The Hesperidin Coronavirus Study”.

The MHI’s study will evaluate the effect of hesperidin on COVID-19 symptoms and its ability to reduce disease severity and the need for hospitalization in patients with COVID-19. The randomized, double-blind, placebo controlled study will enroll 216 confirmed COVID-19 symptomatic patients.

“The immune support properties of hesperidin, the medicinal ingredient contained in HESPERCO™ capsules, and its efficacy against other coronavirus strains are well documented in scientific literature. We are extremely proud to contribute in the fight against the COVID-19 virus with the prestigious MHI and our development partner Ingenew”, said Steve Saviuk , Valeo’s CEO. “Our involvement in this study aligns well with our vision to build a Canadian anchor pharmaceutical company and continued commitment to provide Canadian healthcare professionals and patients with innovative solutions to improve quality of life”.

Commenting on the  Montreal Heart Institute’s Hesperidin Coronovirus Study, Pierre Laurin , President and CEO of Ingenew, said: “We are pleased that MHI’s scientists  concur with our scientific findings.”

Read More: https://agoracom.com/ir/ValeoPharma/forums/discussion/topics/755488-valeo-pharma-s-hesperco-capsules-at-the-core-of-montreal-heart-institute-s-hesperidin-coronavirus-clinical-trial/messages/2303992#message

VIDEO – AGORACOM Beyond The Expert Welcomes Venture Capitalist Leigh Hughes To Discuss Mountain Valley MD $MVMD, Valeo Pharma $VPH $VPHIF and Xphyto Therapeutics $XPHY $XPHYF

Posted by AGORACOM-JC at 6:36 PM on Thursday, February 11th, 2021

AGORACOM followers have given us great feedback on our hit series “Beyond The Press Release” (BTPR) in which we speak with small cap CEO’s about important press releases in greater depth and, quite frankly, in layman’s terms for investors to truly understand their significance.  

Nowhere is this more important than in the world of disruptive technologies, biotech and pharma.  Each of these industries share two distinct traits:

  • The possibility for explosive growth with disruptive new products
  • Difficulty in conveying disruptive new products that, by their nature, have never been seen before by investors.

Whereas BTPR tells these stories from the side of small cap public companies, Beyond The Expert (BTE) tells these stories from the perspective of experts on these topics – and we couldn’t think of anyone better to start off this series than Leigh Hughes.  

Leigh is a Venture Capitalist who I’ve personally watched conduct incredible due diligence and invest into many small cap companies that have generated incredible returns over 12-18 month periods.    

Leigh is so good at what he does that many global private equity funds and institutions take his call and often follow him into investments he chooses to make.  Moreover, he serves as an advisor to several small cap companies.

If you ever wanted to truly learn how to become a great small cap investor, it doesn’t get much better than this.  

Without further adieu, watch this great interview with Leigh Hughes and make sure to provide us with your feedback via comments on Twitter, YouTube or wherever you may be watching or listening.

Valeo Pharma’s $VPH.ca $VPHIF Redesca™ Receives Positive Recommendation for Public Reimbursement in Quebec $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 7:55 AM on Monday, January 25th, 2021
Valeo Pharma (@valeo_pharma) | Twitter
  • Received notice of a positive recommendation by Quebec’s Institut national d’excellence en santé et en services sociaux (“INESSS”) to the Health Minister for the inclusion of its Low Molecular Weight Heparin biosimilar (LMWH), Redesca ™ and Redesca ™ HP, on the list of medications covered by the Régie de l’assurance maladie du Québec (RAMQ) for the prevention and treatment of thromboembolic disorders.
  • “We are very pleased to have received a positive recommendation by INESSS, a key milestone in the coming commercial launch of Redesca™”, said Steve Saviuk , Valeo’s CEO.

MONTREAL , Jan. 25, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, announced today  that it has received notice of a positive recommendation by Quebec’s Institut national d’excellence en santé et en services sociaux (“INESSS”) to the Health Minister for the inclusion of its Low Molecular Weight Heparin biosimilar (LMWH), Redesca ™ and Redesca ™ HP, on the list of medications covered by the Régie de l’assurance maladie du Québec (RAMQ) for the prevention and treatment of thromboembolic disorders.

“We are very pleased to have received a positive recommendation by INESSS, a key milestone in the coming commercial launch of Redesca™”, said Steve Saviuk , Valeo’s CEO. “Redesca™ has a long and strong history of safety and efficacy with more than 8 years of proven in-market data internationally. Redesca™ will be available across Canada and Valeo intends to pursue discussions for the inclusion of Redesca on all other provincial formularies. Valeo  is planning to launch Redesca™ during the first half of 2021.”

In addition to being used primarily for treating and preventing deep vein thrombosis and pulmonary embolism, LMWHs are also now increasingly used as a first line of defense tool in the fight against Covid-19. The World Health Organization (“WHO”) issued guidance regarding the prophylaxis use of LMWH to help prevent complications in the clinical management of severe acute respiratory infections when novel coronavirus (COVID-19) infection is suspected.

Read More: https://agoracom.com/ir/ValeoPharma/forums/discussion/topics/753839-valeo-pharma-s-redesca-receives-positive-recommendation-for-public-reimbursement-in-quebec/messages/2300008#message

VIDEO – Valeo Pharma $VPH.ca $VPHIF Starts Off 2021 With A Bang As MDBriefcase Validates Key Ingredients In Its Immune System Support Product $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 5:57 PM on Tuesday, January 19th, 2021
Valeo Pharma (@valeo_pharma) | Twitter

Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies. 

This model has resulted in the following success:

  • $5.3M in revenues in the first 9 months of 2020 (ending July 31, 2020)
  • 9 products currently in the market with an annual estimated peak sales of $40M/year
  • 7 products in the pipeline with an annual estimated peak sales of $45M/year

In fact, capital markets confidence is so high that Valeo secured $8.6M in financing in the last half of the year with:

  • $6.9M Bought Deal financing at $1.20/shares
  • A $1.7M Oversubscribed debenture (non-convertible) 

If that was all Valeo had, most investors would be happy to sit back and watch the Company grow.

But then came Redesca.  We are going to save you the science and tell you that Redesca belongs to a class of anticoagulant medications (blood thinners) called LMWH.  The size of the Canadian LMWH market is over $200M per year and Valeo believes they can capture 15-30% of this market.  If you’re doing back of napkin math, that equates to $30,000,000 – $60,000,000 per year in revenues.

But how does a new product capture that much market share?  Glad you asked because we asked CEO Steve Saviuk the same question.  Competition is tough in all markets and they don’t let someone take 15-30% market share without one hell of a fight. 

Saviuk agreed and gave the following reasons:

1.  Redesca has an 8-year international track record of safety and efficacy.  It is already well known

2. Redesca is flat out cheaper, which is music to the ears of Provincial Health Ministries whose budgets have been stretched to the max this year no thanks to COVID-19.  

Vaelo is so confident that it stated “This is great news for the Canadian healthcare system …. and is expected to help provide significant savings to provincial healthcare systems.”

Well there you have it.  Valeo is a great story. Watch the video.

HOLD ON. THERE’S MORE … A LOT MORE

In a recently issued newsletter by MDBriefCase entitled “Exploring Novel Therapeutic Approaches for Covid-19: Hesperidin vs Vitamin C” the newsletter stated that recently accumulated evidence suggests that Hesperidin supplementation may be useful as a prophylactic agent against SARS-Cov-2 infection and as a complementary treatment during COVID-19 disease.  What does this mean?

  • Growing body of research suggests Hesperidin may interfere with SARS-CoV-2 infection process
  • Hesperidin may help against Covid-19 viral replication
  • Hesperidin is a potent antioxidant with anti-inflammatory activity that may help in controlling cytokine storm (where the body starts to attack its own cells and tissue rather than just the virus)
  • Valeo’s unique Hesperidin formulation (HESPERCO) is the only format available where every capsule contains 500mg of concentrated Hesperidin.

Now you have it.  That’s the Valeo story as it applies to just 2 of their amazing products.  There is a whole lot more to the story given their pipeline of products but we couldn’t cover it all in this great interview with CEO Steve Saviuk.

If you love revenue generating, growing and blue sky potential small cap companies, then this Valeo interview is a must watch.

Valeo Pharma $VPH.ca $VPHIF Announces Major Addition to its Senior Management Team $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 7:14 AM on Monday, January 18th, 2021
Valeo Pharma (@valeo_pharma) | Twitter
  • Frederic Fasano named President and COO
  • Steve Saviuk continues as CEO and becomes Vice-Chairman of the Board of Directors

MONTREAL , Jan. 18, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, announced today the appointment of Mr. Frederic Fasano to the newly created position of President and Chief Operating Officer, effective January 18th , to augment its senior leadership team and support expansion of Valeo’s commercial activities. Mr. Fasano has also been elected to the Company’s Board of Directors effective as of today.

“It gives me true pleasure to welcome Frederic to the Valeo executive team in this important new role. He possesses extensive International pharmaceutical experience and his management skills are well suited to helping us build a leading innovative pharmaceutical company with a deep commitment to our selected therapeutic areas of focus”, said Steve Saviuk,  CEO. “This increase in management depth, coupled with our solid foundation of products and people, positions us well for the dynamic growth we foresee in the coming years.”

Read More: https://agoracom.com/ir/ValeoPharma/forums/discussion/topics/753244-valeo-pharma-announces-major-addition-to-its-senior-management-team/messages/2298542#message

AGORACOM Small Cap 60: Valeo Pharma $VPH.ca $VPHIF Discusses Health Canada Approval for Redesca™ and Redesca Hp™ $30 Million Forecasted Annual Peak Sales $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 12:14 PM on Thursday, January 14th, 2021
Valeo Pharma (@valeo_pharma) | Twitter
  • Commercial launch to impact first half 2021 revenue
  • $30 million forecasted annual peak sales
  • 8 years of proven in-market safety Internationally
  • Low molecular weight heparin increasingly used to prevent COVID-19 driven complications

“The regulatory approval of Redesca is a significant corporate milestone for Valeo and also great news for the Canadian healthcare system. Mandatory use of biosimilars is increasingly  being adopted across the country and is expected to help provide significant savings to provincial healthcare plans”, said Steve Saviuk , President and CEO. “With more than 8 years of proven in-market safety internationally and a robust supply chain ensuring product availability, we expect Redesca to play a major role in the achievement of our growth objectives”.

Hub On AGORACOM / Corporate Profile